Compare XBIT & AIRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XBIT | AIRS |
|---|---|---|
| Founded | 2005 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Pharmaceuticals and Biotechnology | Medical/Nursing Services |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 73.2M | 328.7M |
| IPO Year | 2015 | 2021 |
| Metric | XBIT | AIRS |
|---|---|---|
| Price | $2.46 | $5.28 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 21.4K | ★ 1.4M |
| Earning Date | 05-08-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $151,818,000.00 |
| Revenue This Year | N/A | $5.19 |
| Revenue Next Year | N/A | $5.32 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.09 | $1.51 |
| 52 Week High | $3.61 | $12.00 |
| Indicator | XBIT | AIRS |
|---|---|---|
| Relative Strength Index (RSI) | 45.30 | 81.90 |
| Support Level | $2.15 | $2.40 |
| Resistance Level | $2.49 | $6.90 |
| Average True Range (ATR) | 0.06 | 0.44 |
| MACD | -0.01 | 0.12 |
| Stochastic Oscillator | 30.43 | 90.80 |
XBiotech Inc is a biopharmaceutical company that discovers and develops True Human monoclonal antibodies derived from human donors to replicate the human immune response in the treatment of various diseases. It has developed a pipeline of product candidates using True Human antibodies targeting both inflammatory and infectious diseases. The company's developement pipeline comprises: Natrunix, an antibody targeting IL-1a in oncology (pancreatic cancer), a clinical stage therapeutic for Methicillin Resistant Staphylococcus aureus (MRSA), and several pre-clinical stage therapeutics, including: an oral delivery antibody therapeutic for colon infection by C. difficile; an injectable therapy for varicella zoster (adult chicken pox), the causative agent for shingles; and an influenza therapy.
AirSculpt Technologies Inc is a next-generation body contouring treatment designed to optimize both comfort and precision, available exclusively at AirSculpt offices. The minimally invasive procedure removes fat and tightens skin while sculpting targeted areas of the body, allowing for quick healing with minimal bruising, tighter skin, and precise results. Its proprietary and patented AirSculpt method is minimally invasive because it requires no needle, no scalpel, no stitches, and no general anesthesia. It offers fat removal procedures across treatment areas and fat transfer procedures that use the patient's own fat cells to enhance the breasts, buttocks, hips or other areas and do not require silicone or foreign materials to be implanted. Its segment is direct medical procedure services.